DE986382T1 - Raf kinase hemmer - Google Patents
Raf kinase hemmerInfo
- Publication number
- DE986382T1 DE986382T1 DE0986382T DE98923601T DE986382T1 DE 986382 T1 DE986382 T1 DE 986382T1 DE 0986382 T DE0986382 T DE 0986382T DE 98923601 T DE98923601 T DE 98923601T DE 986382 T1 DE986382 T1 DE 986382T1
- Authority
- DE
- Germany
- Prior art keywords
- co2ch3
- ch3ooc
- formulas
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009929 raf Kinases Human genes 0.000 title claims abstract 3
- 108010077182 raf Kinases Proteins 0.000 title claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12642097P | 1997-05-23 | 1997-05-23 | |
| US86302197A | 1997-05-23 | 1997-05-23 | |
| PCT/US1998/010376 WO1998052559A1 (en) | 1997-05-23 | 1998-05-21 | Raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE986382T1 true DE986382T1 (de) | 2001-01-25 |
Family
ID=26824631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0986382T Pending DE986382T1 (de) | 1997-05-23 | 1998-05-21 | Raf kinase hemmer |
| DE69839639T Expired - Lifetime DE69839639D1 (en) | 1997-05-23 | 1998-05-21 | Raf kinase hemmer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69839639T Expired - Lifetime DE69839639D1 (en) | 1997-05-23 | 1998-05-21 | Raf kinase hemmer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0986382B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002500650A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE399007T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU7585598A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2291065C (cg-RX-API-DMAC7.html) |
| DE (2) | DE986382T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0986382T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2153337T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR20010300033T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998052559A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| AU2003204708B2 (en) * | 1997-12-22 | 2006-05-25 | Bayer Healthcare Llc | Inhibition of Raf Kinase using Substituted Heterocyclic Ureas |
| JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| NZ505845A (en) * | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| EP1690853B1 (en) * | 1999-01-13 | 2010-03-10 | Bayer HealthCare LLC | Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (en) * | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| HU230863B1 (hu) * | 1999-01-13 | 2018-10-29 | Bayer Healthcare Llc | Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| MXPA01008440A (es) | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
| CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| TR200102817T2 (tr) | 1999-03-12 | 2002-05-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antiinflamatuar ajanlar olarak faydalı bileşikler |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| US6573409B1 (en) | 1999-07-02 | 2003-06-03 | The Nutrasweet Company | Process for the preparation of 3,3-dimethylbutanal |
| CA2374737C (en) | 1999-07-09 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| DE10050492A1 (de) * | 2000-10-11 | 2002-04-25 | Morphochem Ag | Verfahren zur Herstellung von 5-Oxo-2,5-dihydro-furan-2-carbonsäureamiden und 6-Oxo-3,6-dihydro-2H-pyran-2-carbonsäureamiden |
| US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| MXPA03010724A (es) | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina. |
| EP2363396A1 (en) * | 2001-06-11 | 2011-09-07 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| EP1709965A3 (en) * | 2001-07-11 | 2006-12-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediate diseases |
| EP2305255B1 (en) * | 2001-12-03 | 2012-08-22 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| EP1480973B1 (en) | 2002-02-25 | 2008-02-13 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| AU2003245989A1 (en) | 2002-07-09 | 2004-01-23 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| ES2314443T3 (es) * | 2003-08-15 | 2009-03-16 | Astrazeneca Ab | Tiofenos sustituidos y sus usos. |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| US7507735B2 (en) | 2004-06-17 | 2009-03-24 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| CA2584368A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2006062982A2 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| DE602006017188D1 (de) | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| JP5030947B2 (ja) | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007018137A1 (ja) | 2005-08-05 | 2007-02-15 | Chugai Seiyaku Kabushiki Kaisha | マルチキナーゼ阻害剤 |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| CN102627657B (zh) * | 2012-03-09 | 2015-01-07 | 苏州施亚生物科技有限公司 | 3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法 |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| CN106470974B (zh) | 2014-04-17 | 2019-07-16 | 韩国巴斯德研究所 | 用于治疗病毒感染的化合物 |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| HUE053286T2 (hu) | 2016-10-26 | 2021-06-28 | Ishihara Sangyo Kaisha | Eljárás 3-metil-2-tiofénkarbonsav elõállítására |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61268678A (ja) * | 1985-05-17 | 1986-11-28 | バイエル・アクチエンゲゼルシヤフト | 生産増進剤 |
| US5597719A (en) * | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| EP1019040B1 (en) * | 1997-05-23 | 2004-09-29 | Bayer Corporation | Aryl ureas for the treatment of inflammatory or immunomodulatory diseases |
-
1998
- 1998-05-21 AU AU75855/98A patent/AU7585598A/en not_active Abandoned
- 1998-05-21 DE DE0986382T patent/DE986382T1/de active Pending
- 1998-05-21 DE DE69839639T patent/DE69839639D1/de not_active Expired - Lifetime
- 1998-05-21 JP JP55061898A patent/JP2002500650A/ja active Pending
- 1998-05-21 DK DK98923601T patent/DK0986382T3/da active
- 1998-05-21 WO PCT/US1998/010376 patent/WO1998052559A1/en not_active Ceased
- 1998-05-21 ES ES98923601T patent/ES2153337T3/es not_active Expired - Lifetime
- 1998-05-21 AT AT98923601T patent/ATE399007T1/de not_active IP Right Cessation
- 1998-05-21 CA CA2291065A patent/CA2291065C/en not_active Expired - Fee Related
- 1998-05-21 EP EP98923601A patent/EP0986382B1/en not_active Expired - Lifetime
-
2001
- 2001-06-29 GR GR20010300033T patent/GR20010300033T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0986382A1 (en) | 2000-03-22 |
| WO1998052559A1 (en) | 1998-11-26 |
| EP0986382B1 (en) | 2008-06-25 |
| ES2153337T3 (es) | 2008-11-01 |
| EP0986382A4 (en) | 2001-04-11 |
| CA2291065C (en) | 2010-02-09 |
| DK0986382T3 (da) | 2008-10-20 |
| ATE399007T1 (de) | 2008-07-15 |
| ES2153337T1 (es) | 2001-03-01 |
| CA2291065A1 (en) | 1998-11-26 |
| AU7585598A (en) | 1998-12-11 |
| GR20010300033T1 (en) | 2001-06-29 |
| JP2002500650A (ja) | 2002-01-08 |
| DE69839639D1 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5683396B2 (ja) | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 | |
| DE60217503T2 (de) | N-phenylpyrrol guanidin derivate als melanocortinrezeptor liganden | |
| WO2000039082A3 (en) | 1,2-annelated quinoline derivatives | |
| RU2005120003A (ru) | Производные изоиндолина | |
| DE1041982T1 (de) | HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN | |
| ATE181735T1 (de) | Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten | |
| DK0468470T3 (da) | Benzimidazoler, lægemidler indeholdende sådanne forbindelser og fremgangsmåde til deres fremstilling | |
| ATE206130T1 (de) | Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung | |
| EP0303465A3 (en) | Phenethanolamine derivatives | |
| NZ332658A (en) | Halo-substituted bis-indolylmaleimide derivatives and pharmaceutical compositions | |
| TW340115B (en) | Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis | |
| IT1250749B (it) | Composti eterociclici ad attivita' a ii antagonista | |
| IS5588A (is) | Æxliseyðandi miðlar | |
| MX9706394A (es) | Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1. | |
| DE1032264T1 (de) | Verfahren zur erhöhung der antimikrobiellen eigenschaften von antibakteriellen antibiotika | |
| DE69700308T2 (de) | Kovalentgebundene Dimere von Glykopeptid-Antibiotika | |
| AT394194B (de) | Verfahren zur herstellung neuer 5-pyrimidincarboxamide und -thiocarboxamide | |
| CO5261527A1 (es) | Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina | |
| ATE49749T1 (de) | Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen. | |
| DE69201559T2 (de) | Pyrimidinderivate zur erhöhung der antitumoraktivität. | |
| DE2550851A1 (de) | N-(3,4,5-trimethoxycinnamoyl)- piperazinderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
| Brown et al. | The pharmacologic properties of 2-[α-(2-dimethylaminoethoxy)-α-methylbenzyl]-pyridine succinate, a new antihistaminic agent | |
| DE2006446A1 (cg-RX-API-DMAC7.html) | ||
| DE19509670A1 (de) | Verbindungen der s-Triazinreihe | |
| DE59104930D1 (de) | Hydrazone. |